Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data

Julia Driessen, Fer de Wit, Alex F. Herrera, Pier Luigi Luigi Zinzani, Ann S. LaCasce, Craig H. Moskowitz, Ramon Garcia-Sanz, Peter D. Cole, Michael Fuchs, Horst Mueller, Peter Borchmann, Heiko Schöder, Josée M Zijlstra, Barbara A. Hutten, Alison J. Moskowitz, Marie José Kersten

Blood (2021) 138 (Supplement 1): 879.

https://doi.org/10.1182/blood-2021-147810

Published: 2021

Journal Articles

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Conrad-Amadeus Voltin, Jasmin Mettler, MD, Horst Mueller, PhD, Michael Fuchs, MD, Christian Baues, MD, Markus Dietlein, MD, Andreas Engert, MD, Peter Borchmann, MD PhD, Carsten Kobe, Paul J Bröckelmann, MD

Blood (2019) 134 (Supplement_1): 4020.

https://doi.org/10.1182/blood-2019-123641

Published: 2019

Journal Articles

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Bastian von Tresckow, MD, Andreas Hüttmann, MD, Vladan Vucinic, MD, Horst Mueller, PhD, Annette Plütschow, Andreas Viardot, MD, Max S. Topp, Carsten Kobe, MD, Boris Böll, MD, Dennis A. Eichenauer, Stephanie Sasse, MD, Heinz Haverkamp, Michael Fuchs, Andreas Engert, MD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2018-99-117291

Published: 2018

Journal Articles

Clinical Outcomes of Patients with 3 rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group

Paul Broeckelmann, Horst Mueller, PhD, Esra Kücüksarioglan, Peter Kaskel, MD MBA, Veronika Metterlein, MPH, Hilde Giezek, MSc Biostatistics, Arun Balakumaran, MD PhD, Monika Raut, PhD MS, Andreas Engert, MD, Bastian von Tresckow

Blood (2017) 130 (Supplement 1): 2793.

https://doi.org/10.1182/blood.V130.Suppl_1.2793.2793

Published: 2017

Journal Articles

Fatigue in Hodgkin Lymphoma Patients: Longitudinal Evaluation and Curve Types up to 5 Years

Stefanie Kreissl, MD, Horst Mueller, PhD, Axel Mayer, Karolin Behringer, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 854.

https://doi.org/10.1182/blood.V124.21.854.854

Published: 2014

Journal Articles

Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials.

Blood (2012) 120 (21): 2636.

https://doi.org/10.1182/blood.V120.21.2636.2636

Published: 2012

Journal Articles

Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG)

Stephanie Sasse, MD, Magdalena Alram, Medical Student, Horst Mueller, PhD, Lenka Smardova, MD, Bernd Metzner, Hartmut Döhner, MD, Thomas Fischer, MD, Vladan Vucinic, Norbert Schmitz, MD, Kerstin Schäfer-Eckart, John M. Raemaekers, MD, PhD, Oliver Schmalz, MD, Bastian von Tresckow, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2012) 120 (21): 552.

https://doi.org/10.1182/blood.V120.21.552.552

Published: 2012

Journal Articles

Fertility and Gonadal Function After Treatment of Early Unfavorable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG)

Karolin Behringer, MD, Indra Thielen, MD, Horst Mueller, Helen Goergen, Angelika Eibl, Johannes Rosenbrock, Teresa Halbsguth, MD, Katrin S. Reiners, PhD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2011) 118 (21): 432.

https://doi.org/10.1182/blood.V118.21.432.432

Published: 2011

Journal Articles

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

Teresa V. Halbsguth, Lucia Nogová, Horst Mueller, Michal Sieniawski, Dennis A. Eichenauer, Thomas Schober, Hiltrud Nisters-Backes, Peter Borchmann, Volker Diehl, Andreas Engert, Andreas Josting

Blood (2010) 116 (12): 2026–2032.

https://doi.org/10.1182/blood-2009-11-253211

Published: 2010

Journal Articles

No Reduction of Ovarian Failure with the Use of GnRH-Analogues or Oral Contraceptives in Young Women Treated with Escalated BEACOPP for Advanced-Stage Hodgkin Lymphoma (HL). Final Results of the PROFE Trial, German Hodgkin Study Group (GHSG).

Karolin Behringer, Ludwig Wildt, Horst Mueller, Helmut-Werner Ott, Susanne Hofer, Volker Diehl, Beate van den Hoonard, Andreas Engert, Peter Borchmann

Blood (2009) 114 (22): 3710.

https://doi.org/10.1182/blood.V114.22.3710.3710

Published: 2009

Journal Articles

“Quality of Life (QoL) in the Randomised HD10-12 Trials of the German Hodgkin Study Group (GHSG): Sexual Functions (SX) in Hodgkin Lymphoma (HL) Patients Decrease by Disease Stage and Improve After Therapy Depending On Stage and Treatment Modality.”.

Karolin Behringer, Horst Mueller, Hans-Henning Flechtner, Corinne Brillant, Teresa Halbsguth, Thomas Schober, Hiltrud Nisters-Backes, Andreas Engert, MD, Peter Borchmann

Blood (2009) 114 (22): 896.

https://doi.org/10.1182/blood.V114.22.896.896

Published: 2009

Journal Articles

Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial.

Peter Borchmann, Volker Diehl, Helen Goergen, Horst Mueller, Rolf Peter Mueller, Hans T. Eich, Hans Konrad Mueller-Hermelink, Richard Herrmann, MD, Jana Markova, Anthony D. Ho, MD, PhD, Wolfgang Hiddemann, Bernd Doerken, Richard Greil, Andreas Engert, MD

Blood (2009) 114 (22): 717.

https://doi.org/10.1182/blood.V114.22.717.717

Published: 2009

Journal Articles

Hodgkin Lymphoma in Adolescents Treated with Adult Protocols: An Analysis From the German Hodgkin Study Group (GHSG).

Dennis A. Eichenauer, Henning Bredenfeld, Jeremy Franklin, Heinz Haverkamp, Horst Mueller, Hans T. Eich, Rolf-Peter Mueller, Michael Fuchs, Peter Borchmann, Volker Diehl, Andreas Engert

Blood (2009) 114 (22): 719.

https://doi.org/10.1182/blood.V114.22.719.719

Published: 2009

Journal Articles

Quality of Life in a 2-Year Follow-up: Signs of PNP Predicting Cognitive Functioning in Survivors Treated in the HD10–12 Trials of the German Hodgkin Study Group (GHSG).

Teresa Halbsguth, Horst Mueller, Hans-Henning Flechtner, Corinne Brillant, Karolin Behringer, Thomas Schober, Hiltrud Nisters-Backes, Andreas Engert, Peter Borchmann

Blood (2008) 112 (11): 1455.

https://doi.org/10.1182/blood.V112.11.1455.1455

Published: 2008

Journal Articles

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Horst Mueller, Lucia Nogova, Dennis A Eichenauer, Teresa Halbsguth, Hiltrud Nisters-Backes, Thomas Schober, Hartmut Eimermacher, Peter Borchmann, Michael Fuchs, Andreas Engert, Andreas Josting

Blood (2008) 112 (11): 2600.

https://doi.org/10.1182/blood.V112.11.2600.2600

Published: 2008

NARROW

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Clinical Outcomes of Patients with 3 rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group

Fatigue in Hodgkin Lymphoma Patients: Longitudinal Evaluation and Curve Types up to 5 Years

Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials.

Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG)

Fertility and Gonadal Function After Treatment of Early Unfavorable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG)

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

No Reduction of Ovarian Failure with the Use of GnRH-Analogues or Oral Contraceptives in Young Women Treated with Escalated BEACOPP for Advanced-Stage Hodgkin Lymphoma (HL). Final Results of the PROFE Trial, German Hodgkin Study Group (GHSG).

“Quality of Life (QoL) in the Randomised HD10-12 Trials of the German Hodgkin Study Group (GHSG): Sexual Functions (SX) in Hodgkin Lymphoma (HL) Patients Decrease by Disease Stage and Improve After Therapy Depending On Stage and Treatment Modality.”.

Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial.

Hodgkin Lymphoma in Adolescents Treated with Adult Protocols: An Analysis From the German Hodgkin Study Group (GHSG).

Quality of Life in a 2-Year Follow-up: Signs of PNP Predicting Cognitive Functioning in Survivors Treated in the HD10–12 Trials of the German Hodgkin Study Group (GHSG).

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only